Abstract: Materials and Methods related to a transgenic non-human animal (e.g., a transgenic non-human mammal) whose genome comprises a disrupted TIEG allele are provided. Methods for making such transgenic non-human animals, and using them to identify and characterize agents that affect conditions related to TIEG activity, such as cardiac hypertrophy and bone formation also are provided. In addition, materials and methods related to the treatment of hypertrophic cardiomyopathy are provided.

Abstract: Materials and methods related to a transgenic non-human animal (e.g., a transgenic non-human mammal) whose genome comprises a disrupted TIEG allele are provided. Methods for making such transgenic non-human animals, and using them to identify and characterize agents that affect conditions related to TIEG activity, such as cardiac hypertrophy and bone formation also are provided. In addition, materials and methods related to the treatment of hypertrophic cardiomyopathy are provided.

Abstract: The invention provides materials and methods for determining the aggressiveness of a cancer in a mammal. Specifically, the invention provides methods and methods for measuring the level of a TIEG marker in a sample. Such levels can be correlated with the aggressiveness of a cancer to predict patient outcome and develop treatment regimens.

Abstract: Methods to determine TIEF-1 polypeptide, or genetic rearrangements in the TIEF-1 gene, in a sample are provided. Also provided are TIEF-1 specific antibodies and nucleic acid probes, and methods of employing those antibodies and probes to detect breast cancer in situ in a mammalian tissue sample.

Abstract: An isolated and purified DNA molecule encoding TGF-.beta. inducible early factor-1 (TIEF-1) is provided. A method of isolating a growth factor- or differentiation factor-inducible gene is also provided.

Abstract: Immortalized normal human fetal osteoblastic cells that express a temperature sensitive mutant of simian virus 40 large T antigen are provided.

Abstract: Immortalized normal human fetal osteoblastic cells that express a temperature sensitive mutant of simian virus 40 large T antigen are provided.

Abstract: Immortalized normal human fetal osteoblastic cells that express a temperature sensitive mutant of simian virus 40 large T antigen are provided.

Abstract: A method and a test kit for rapidly determining the presence of functional cellular steroid receptors by assaying a tissue sample for nuclear steroid or antisteroid binding is disclosed which comprises treating the tissue with collagenase, incubating the isolated cells with a labelled steroid or a labelled antisteroid capable of complexing said receptors and measuring the bound nuclear radioactivity and the DNA of the isolated cellular nuclei.

Abstract: A method for rapidly determining the presence of functional cellular steroid receptors by assaying a tissue sample for nuclear steroid or antisteroid binding is disclosed which comprises treating the tissue with collagenase, incubating the isolated cells with a labelled steroid or a labelled antisteroid capable of complexing said receptors and measuring the bound nuclear radioactivity and the DNA of the isolated cellular nuclei.

Abstract: A method for rapidly determining the presence of functional cellular steroid receptors by assaying a tissue sample for nuclear steroid binding is disclosed which comprises treating the tissue with collagenase, incubating the isolated cells with a labelled steroid capable of complexing said receptors and measuring the bound radioactivity and the DNA of the isolated cellular nuclei.

Abstract: A continuous flow tissue homogenizer is disclosed and includes a generally tubular container (12) with an inner surface (60) defining a tissue homogenization chamber (19). One end of the container has an inlet (46) for the introduction of non-homogenized tissue in solution and the other end of the container has an outlet (36) for the discharge of homogenate. A pestle member (38) is disposed within the homogenization chamber and mounted to a shaft (40) for rotatably driving the pestle member. The pestle member has an outer surface (62) that is spaced apart from the inner surface of the container to provide a tissue disruption zone (64) therebetween. The pestle member divides the homogenization chamber into first portion (54) and second portion (56). A plurality of grooves (68) are circumferentially spaced about the outer surface of the pestle member and open into the first chamber portion to channel the tissue solution into the tissue disruption zone of the apparatus.